(Q46452847)

22 December 2017

title

Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection (English)

1 reference

22 December 2017

author name string

K Pham

1

1 reference

22 December 2017

K Kraft

2

1 reference

22 December 2017

J Thielke

3

1 reference

22 December 2017

J Oberholzer

4

1 reference

22 December 2017

H Sankary

5

1 reference

22 December 2017

G Testa

6

1 reference

22 December 2017

E Benedetti

7

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

22 December 2017

Transplantation Proceedings

published in

1 reference

22 December 2017

volume

37

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

899-902

1 reference

22 December 2017

Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.079

The use of antibodies against the IL-2 receptor in transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.079

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.079

Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.079

Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.079

Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.079

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.079

Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.079

A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas tran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.079

10.1016/J.TRANSPROCEED.2004.12.079

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017